<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859244</url>
  </required_header>
  <id_info>
    <org_study_id>CC-2021-001</org_study_id>
    <nct_id>NCT04859244</nct_id>
  </id_info>
  <brief_title>First-in-Human Study of Orally Administered GS-441524 for COVID-19</brief_title>
  <official_title>First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of Orally Administered GS-441524 in a Healthy Human Volunteer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copycat Sciences LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Copycat Sciences LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-part study is to evaluate the multi-day safety, tolerability, and&#xD;
      pharmacokinetics (PK) of orally administered GS-441524 in a healthy human volunteer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: 750 mg GS-441524 administered once daily (QD) for 7 days. Part 2: 750 mg GS-441524&#xD;
      administered three times daily (TID) for 3 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">May 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Emergence of treatment-related adverse events (AEs)</measure>
    <time_frame>Day 7</time_frame>
    <description>Treatment-related AEs are defined as significant changes to blood chemistry (CBC, CMP) or 6-lead ECG.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUC0-24h of GS-441524 in Parts 1 and 2.</measure>
    <time_frame>Intensive PK: Day 1 to Day 7</time_frame>
    <description>AUC0-24h is defined as the concentration of drug over time between time 0 to time 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUClast of GS-441524 in Parts 1 and 2.</measure>
    <time_frame>Intensive PK: Day 1 to Day 7</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: T1/2 of GS-441524 in Parts 1 and 2.</measure>
    <time_frame>Intensive PK: Day 1 to Day 7</time_frame>
    <description>T/2 is defined as the estimate of the terminal elimination half-life of the drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmax of GS-441524 in Parts 1 and 2.</measure>
    <time_frame>Intensive PK: Day 1 to Day 7</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Tmax of GS-441524 in Parts 1 and 2.</measure>
    <time_frame>Intensive PK: Day 1 to Day 7</time_frame>
    <description>Tmax is defined as the time (observed time point) of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Clast of GS-441524 in Parts 1 and 2.</measure>
    <time_frame>Intensive PK: Day 1 to Day 7</time_frame>
    <description>Clast is defined as the last observable concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Tlast of GS-441524 in Parts 1 and 2.</measure>
    <time_frame>Intensive PK: Day 1 to Day 7</time_frame>
    <description>Tlast is defined as the time (observed time point) of Clast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUCtau of GS-441524 in Parts 1 and 2.</measure>
    <time_frame>Intensive PK: Day 1 to Day 7</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Part 1: GS-441524 (QD, 7 days)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>750 mg GS-441524 administered QD for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: GS-441524 (TID, 3 days)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>750 mg GS-441524 administered TID for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-441524</intervention_name>
    <description>750 mg administered as a solution</description>
    <arm_group_label>Part 1: GS-441524 (QD, 7 days)</arm_group_label>
    <arm_group_label>Part 2: GS-441524 (TID, 3 days)</arm_group_label>
    <other_name>Parent nucleoside of remdesivir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Negative pregnancy test at screening and prior to dosing&#xD;
&#xD;
          -  Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of other investigational drugs within 28 days of dosing&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Abuse of alcohol or drugs&#xD;
&#xD;
          -  Other clinically significant medical conditions or laboratory abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victoria Yan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copycat Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Copycat Sciences Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://osf.io/am5s8/</url>
    <description>Preliminary results</description>
  </link>
  <reference>
    <citation>Humeniuk R, Mathias A, Cao H, Osinusi A, Shen G, Chng E, Ling J, Vu A, German P. Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. Clin Transl Sci. 2020 Sep;13(5):896-906. doi: 10.1111/cts.12840. Epub 2020 Aug 5.</citation>
    <PMID>32589775</PMID>
  </reference>
  <reference>
    <citation>Tempestilli M, Caputi P, Avataneo V, Notari S, Forini O, Scorzolini L, Marchioni L, Ascoli Bartoli T, Castilletti C, Lalle E, Capobianchi MR, Nicastri E, D'Avolio A, Ippolito G, Agrati C; COVID 19 INMI Study Group. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother. 2020 Oct 1;75(10):2977-2980. doi: 10.1093/jac/dkaa239.</citation>
    <PMID>32607555</PMID>
  </reference>
  <reference>
    <citation>Davis MR, Pham CU, Cies JJ. Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis. J Antimicrob Chemother. 2021 Feb 11;76(3):822-825. doi: 10.1093/jac/dkaa472.</citation>
    <PMID>33152758</PMID>
  </reference>
  <reference>
    <citation>Yan VC, Muller FL. Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment. ACS Med Chem Lett. 2020 Jun 23;11(7):1361-1366. doi: 10.1021/acsmedchemlett.0c00316. eCollection 2020 Jul 9.</citation>
    <PMID>32665809</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>August 7, 2021</last_update_submitted>
  <last_update_submitted_qc>August 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GS-441524</keyword>
  <keyword>remdesivir</keyword>
  <keyword>GS-5734</keyword>
  <keyword>Copycat Sciences</keyword>
  <keyword>Gilead Sciences</keyword>
  <keyword>COVID-19</keyword>
  <keyword>antiviral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remdesivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected IPD</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Within 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>Materials available upon request</ipd_access_criteria>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://osf.io/am5s8/</doc_url>
      <doc_comment>Supplementary Table 1: Blood chemistry (CBC, CMP) results. Supplementary Table 2: Plasma concentrations of GS-441524 at indicated timepoints.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

